Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Briana Rose HalleAllison Betof WarnerFarzana Y ZamanAndrew HaydonPrachi BhaveAnna K DewanFei YeRebecca IrlmeierParas MehtaNicholas R KurtanskyMario E LacoutureJessica C HasselJacob S ChoiJeffrey A SosmanSunandana ChandraTracey S OttoRyan J SullivanMeghan J MooradianSteven T ChenFlorentia DimitriouGeorgina LongMatteo CarlinoAlexander MenziesDouglas B JohnsonVeronica M RotembergPublished in: Journal for immunotherapy of cancer (2022)
In this multicenter study, ICI therapy was associated with frequent psoriasis exacerbation, although flares were manageable with standard psoriasis treatments and few required ICI discontinuation. Patients who experienced disease exacerbation performed at least as well as those who did not. Thus, pre-existing psoriasis should not prevent patients from receiving ICIs for treatment of malignancy.